Related Experiment Video
Updated: Jul 11, 2026
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
Published on: January 31, 2020
NKG2A inhibits TH2 cell effector function in vitro
Robert J Freishtat1, Bahar Mojgani, Maryam Nazemzadeh
1Division of Emergency Medicine, Children's National Medical Center, Washington, DC, USA. rfreishtat@cnmcresearch.org
Insights
Signaling through NKG2A inhibits T helper 2 (TH2) cell function, indicated by reduced IL-4 production. This finding suggests NKG2A agonists could modulate Th1/Th2 balance in Th2-dominant diseases.
Area of Science:
- Immunology
- Cellular Immunology
- T cell differentiation
Background:
- NKG2A, an inhibitory receptor, binds HLA-E and is expressed on activated TH2 cells.
- Previous work established NKG2A expression on TH2 but not TH1 cells.
Purpose of the Study:
- To investigate the functional impact of NKG2A signaling on human ex vivo TH2 cells.
- To measure cytokine production in TH2 cells stimulated with an NKG2A-specific agonist.
Main Methods:
- Human TH2 cells were purified and activated using anti-CD3/28 antibodies.
- Cells were challenged with an NKG2A-specific agonist, and IL-4 production was measured via flow cytometry.
Main Results:
- Activation increased NKG2A expression on TH2 cells (7.3% to 13.7%, p=0.03).
- NKG2A agonist stimulation significantly reduced intracellular IL-4 expression in activated TH2 cells (25.5% to 9.3%, p=0.001).
- NKG2A agonist did not alter NKG2A expression levels.
Conclusions:
- NKG2A signaling suppresses TH2 effector function, specifically IL-4 production.
- Targeting NKG2A may offer a therapeutic strategy for diseases characterized by Th2 cytokine dominance.
Background:
We previously reported that NKG2A, a key inhibitory ligand for HLA-E, is expressed on activated TH2 but not TH1 cells. Here we measured cytokine expression in human ex vivo TH2 cells upon activation with anti-CD3/28 and challenge with an NKG2A-specific agonist.
Methods:
TH2 cells were purified from healthy volunteers and activated with anti-CD3/28 in the presence and absence of NKG2A-specific agonist. IL-4 was used as a marker of TH2 effector function and measured by flow cytometry.
Results:
Activation of TH2 cells increased NKG2A positivity from (Mean +/- SE) 7.3 +/- 2.4% to 13.7 +/- 3.8%; (p = 0.03). The presence of NKG2A agonist did not significantly alter NKG2A expression, however, the percentage of activated TH2 cells expressing intracellular IL-4 decreased from 25.5 +/- 6.8% to 9.3 +/- 4.8% (p = 0.001).
Conclusion:
We show that signalling through NKG2A suppresses TH2 effector function. This may provide a means to modulate Th1/Th2 balance in diseases where Th2 cytokines predominate.
